Latest & greatest articles for amiodarone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on amiodarone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on amiodarone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for amiodarone

1. Amiodarone

of phlebitis in patients taking peripherally infused amiodarone : A randomized clinical trial. 31-35 S1062-0303(16)30111-X 10.1016 (...) /j.jvn.2016.11.001 Intravenous amiodarone is considered an effective treatment option for cardiac ventricular and atrial arrhythmias. Peripheral infusion of amiodarone may cause blood vessels irritation and phlebitis that is the most common complication of this drug by this route even when it is administered within recommended dosing limits. The effect of injection-site (...) Amiodarone Top results for amiodarone - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4

2018 Trip Latest and Greatest

2. In Patients With Cardiac Arrest, Does Amiodarone or Lidocaine Increase Meaningful Survival?

In Patients With Cardiac Arrest, Does Amiodarone or Lidocaine Increase Meaningful Survival? TAKE-HOME MESSAGE Among out-of-hospital cardiac arrest patients with shock-refractory ventricular tachycardia or ventricular ?brillation, neither amiodarone nor lidocaine increases survival to hospital discharge or good neurologic outcome. In Patients With Cardiac Arrest, Does Amiodarone or Lidocaine Increase Meaningful Survival? EBEM Commentators Benton R. Hunter, MD Paul I. Musey, MD Department (...) of Emergency Medicine Indiana University School of Medicine Indianapolis, IN Results Threerandomizedcontrolledtrials (n¼3,677) and 4 observational studies (n¼704) were included for meta-analysis out of 528 articles identi?edontheinitialsearch.The results were driven by a single large (n¼3,026) randomized controlled trial at low risk of bias. The 2 smaller randomized con- trolled trials had moderate risk of bias, and the observational studies were generally at low risk of bias. Both lidocaine and amiodarone

2017 Annals of Emergency Medicine Systematic Review Snapshots

3. Amiodarone: Wonder Drug or Wonder Why?

Amiodarone: Wonder Drug or Wonder Why? Emergency Medicine > Journal Club > Archive > January 2018 Toggle navigation January 2018 Amiodarone: Wonder Drug or Wonder Why? Vignette Working in TCC can be draining, and on one particularly busy afternoon, you begin to suspect your own sanity. After back-to-back cardiac arrest patients, you wonder if perhaps you should have done something less stressful with your life, like maybe become a lobster boat captain or an ice road trucker. Your first code (...) is a middle-aged female who suffered cardiac arrest while watching Alabama beat Clemson during the Sugar Bowl (yeah...that's right!!!). She was initially noted to be in ventricular fibrillation (VF), and remained so after three rounds of defibrillation. As she arrives in the trauma room, you immediately continue CPR and set up to shock her again. Your attending orders amiodarone, and even though you remember hearing that this may not be very effective, you realize it's not the time to argue. The patient

2018 Washington University Emergency Medicine Journal Club

4. An implantable cardioverter defibrillator but not amiodarone reduced risk of death in congestive heart failure Full Text available with Trip Pro

An implantable cardioverter defibrillator but not amiodarone reduced risk of death in congestive heart failure An implantable cardioverter defibrillator but not amiodarone reduced risk of death in congestive heart failure | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here An implantable cardioverter defibrillator but not amiodarone reduced risk of death in congestive heart failure Article Text Therapeutics An implantable cardioverter

2006 Evidence-Based Medicine

5. Amiodarone and lidocaine in refractory cardiac arrest

Amiodarone and lidocaine in refractory cardiac arrest Amiodarone and lidocaine in refractory cardiac arrest | Heart by Out of hospital cardiac arrest with shock-refractory ventricular tachycardia (VT) or fibrillation (VF) carries a severe prognosis. Despite their frequent use and guideline inclusion in this scenario, evidence that amiodarone or lidocaine improve survival is lacking. In this large multicenter randomized controlled double-blind trial, 3026 adult patients with spontaneously (...) occurring out-of-hospital cardiac arrest and shock-refractory VT or VF were randomized by paramedics to treatment with amiodarone (974), lidocaine (993) or saline placebo (1059), along with standard care. After presentation to the hospital, patients received open-label drugs, emergent angiography, and cooling as clinically indicated. The primary outcome was survival to discharge with secondary outcomes including neurological and functional status in survivors. Mean time to paramedic arrival and study

2017 Heart JournalScan Blog

6. Amiodarone versus Lidocaine for Arrhythmias: Comparative Clinical Effectiveness

Amiodarone versus Lidocaine for Arrhythmias: Comparative Clinical Effectiveness Amiodarone versus Lidocaine for Arrhythmias: Comparative Clinical Effectiveness | CADTH.ca Find the information you need Amiodarone versus Lidocaine for Arrhythmias: Comparative Clinical Effectiveness Amiodarone versus Lidocaine for Arrhythmias: Comparative Clinical Effectiveness Published on: January 8, 2016 Project Number: RB0949-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type (...) : Report Question What is the comparative clinical effectiveness of intravenous amiodarone versus intravenous lidocaine for patients in cardiac arrest or with life-threatening arrhythmias? Key Message One systematic review, two randomized controlled trials, and one non-randomized study were identified regarding intravenous amiodarone versus intravenous lidocaine for arrhythmias. Tags amiodarone, death, heart arrest, lidocaine, heart attack, Arrhythmias, Cardiac, Cardiac, Sudden Files Rapid Response

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

7. Amiodarone

Amiodarone Amiodarone Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Amiodarone Amiodarone Aka: Amiodarone , Cordarone From Related (...) -butyl-3-benzofuranyl)(4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl)- , Amiodarone [Chemical/Ingredient] , AMIODARONE , amiodarone , Amiodarone (product) , Amiodarone (substance) Swedish Amiodaron Czech amiodaron Finnish Amiodaroni Russian AMIODARON , АМИОДАРОН Japanese アミオダロン Polish Amiodaron Spanish amiodarona (producto) , amiodarona (sustancia) , amiodarona , Amiodarona French Amiodarone German Amiodaron Italian Amiodarone Portuguese Amiodarona Derived from the NIH UMLS ( ) Ontology: Cordarone

2018 FP Notebook

8. Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study Full Text available with Trip Pro

Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study Intravenous procainamide and amiodarone are drugs of choice for well-tolerated ventricular tachycardia. However, the choice between them, even according to Guidelines, is unclear. We performed a multicentre randomized open-labelled study to determine the safety and efficacy of intravenous procainamide and amiodarone for the acute treatment (...) of tolerated wide QRS complex (probably ventricular) tachycardia.Patients were randomly assigned to receive intravenous procainamide (10 mg/kg/20 min) or amiodarone (5 mg/kg/20 min). The primary endpoint was the incidence of major predefined cardiac adverse events within 40 min after infusion initiation. Of 74 patients included, 62 could be analysed. The primary endpoint occurred in 3 of 33 (9%) procainamide and 12 of 29 (41%) amiodarone patients (odd ratio, OR = 0.1; 95% confidence interval, CI 0.03-0.6

2016 EvidenceUpdates Controlled trial quality: predicted high

9. Amiodarone-Induced Thyrotoxicosis Recurrence After Amiodarone Reintroduction. (Abstract)

Amiodarone-Induced Thyrotoxicosis Recurrence After Amiodarone Reintroduction. Reintroduction of amiodarone in patients with a history of amiodarone-induced thyrotoxicosis (AIT) is rarely used. To date, the risk of AIT recurrence after amiodarone reintroduction is unpredicted. The aim of the study was to evaluate the risk of AIT recurrence. Retrospectively, from 2000 to 2011, all euthyroid patients with a history of AIT with amiodarone reintroduction were included. Type and severity of the first (...) AIT, amiodarone chronology, and thyroid function evolution after reintroduction of amiodarone were investigated: 46 of 172 patients with AIT history needed amiodarone reintroduction. At first AIT episode, the mean age was 62.2 ± 16 years with male gender predominance; 65% of patients were classified as type 1 AIT. AIT recurred in 14 patients (30%), 12 patients developed hypothyroidism (26%), and 20 patients remained euthyroid (44%). Characteristics of type 1 AIT during the first episode, namely

2016 American Journal of Cardiology

10. 2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction Full Text available with Trip Pro

2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction Treatment with amiodarone is associated with changes in thyroid function tests, but also with thyroid dysfunction (amiodarone-induced hypothyroidism, AIH, and amiodarone-induced thyrotoxicosis, AIT). Both AIH and AIT may develop in apparently normal thyroid glands or in the presence of underlying thyroid abnormalities. AIH does not require amiodarone withdrawal, and is treated (...) amiodarone in AIT should be individualized in relation to cardiovascular risk stratification and taken jointly by specialist cardiologists and endocrinologists. In the presence of rapidly deteriorating cardiac conditions, emergency thyroidectomy may be required for all forms of AIT.

2018 European thyroid journal

11. Antiarrhythmic Drugs for Non-Shockable-Turned-Shockable Out-of-Hospital Cardiac Arrest: The Amiodarone, Lidocaine or Placebo Study (ALPS). Full Text available with Trip Pro

Antiarrhythmic Drugs for Non-Shockable-Turned-Shockable Out-of-Hospital Cardiac Arrest: The Amiodarone, Lidocaine or Placebo Study (ALPS). Out-of-hospital cardiac arrest (OHCA) commonly presents with nonshockable rhythms (asystole and pulseless electric activity). It is unknown whether antiarrhythmic drugs are safe and effective when nonshockable rhythms evolve to shockable rhythms (ventricular fibrillation/pulseless ventricular tachycardia [VF/VT]) during resuscitation.Adults with nontraumatic (...) OHCA, vascular access, and VF/VT anytime after ≥1 shock(s) were prospectively randomized, double-blind, to receive amiodarone, lidocaine, or placebo by paramedics. Patients presenting with initial shock-refractory VF/VT were previously reported. The current study was a prespecified analysis in a separate cohort that initially presented with nonshockable OHCA and was randomized on subsequently developing shock-refractory VF/VT. The primary outcome was survival to hospital discharge. Secondary

2017 Circulation Controlled trial quality: predicted high

12. Amiodarone method of administration for treatment of post-operative atrial fibrillation

Amiodarone method of administration for treatment of post-operative atrial fibrillation Amiodarone method of administration for treatment of post-operative atrial fibrillation Amiodarone method of administration for treatment of post-operative atrial fibrillation Mitchell MD, Strauss R, Mull N. Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Mitchell MD, Strauss R, Mull N.. Amiodarone method of administration for treatment of post-operative atrial fibrillation. Philadelphia: Center for Evidence-based Practice (CEP). 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Postoperative Period Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence

2016 Health Technology Assessment (HTA) Database.

13. Thyroidectomy for Amiodarone-Induced Thyrotoxicosis: Mayo Clinic Experience Full Text available with Trip Pro

Thyroidectomy for Amiodarone-Induced Thyrotoxicosis: Mayo Clinic Experience Amiodarone-induced thyrotoxicosis (AIT) is a difficult diagnostic and management challenge, especially during severe thyrotoxicosis accompanied by cardiovascular compromise.To evaluate thyroidectomy for the management of AIT.Retrospective cohort study of adults with noncongenital heart disease with AIT after >3 months of amiodarone who underwent thyroidectomy from 1 November 2002 to 31 December 2016.Referral center.The

2018 Journal of the Endocrine Society

14. Meta-analysis of amiodarone versus beta-blocker as a prophylactic therapy against atrial fibrillation following cardiac surgery

Meta-analysis of amiodarone versus beta-blocker as a prophylactic therapy against atrial fibrillation following cardiac surgery Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

15. Amiodarone

Amiodarone Amiodarone Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Amiodarone Amiodarone Aka: Amiodarone , Cordarone From Related (...) -butyl-3-benzofuranyl)(4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl)- , Amiodarone [Chemical/Ingredient] , AMIODARONE , amiodarone , Amiodarone (product) , Amiodarone (substance) Swedish Amiodaron Czech amiodaron Finnish Amiodaroni Russian AMIODARON , АМИОДАРОН Japanese アミオダロン Polish Amiodaron Spanish amiodarona (producto) , amiodarona (sustancia) , amiodarona , Amiodarona French Amiodarone German Amiodaron Italian Amiodarone Portuguese Amiodarona Derived from the NIH UMLS ( ) Ontology: Cordarone

2015 FP Notebook

16. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation Full Text available with Trip Pro

A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation This randomized double-blind study compared the efficacy and safety of intravenous vernakalant and amiodarone for the acute conversion of recent-onset atrial fibrillation (AF).Intravenous vernakalant has effectively converted recent-onset AF and was well tolerated in placebo-controlled studies.A total of 254 adult patients with AF (3 to 48 h duration) eligible (...) for cardioversion were enrolled in the study. Patients received either a 10-min infusion of vernakalant (3 mg/kg) followed by a 15-min observation period and a second 10-min infusion (2 mg/kg) if still in AF, plus a sham amiodarone infusion, or a 60-min infusion of amiodarone (5 mg/kg) followed by a maintenance infusion (50 mg) over an additional 60 min, plus a sham vernakalant infusion.Conversion from AF to sinus rhythm within the first 90 min (primary end point) was achieved in 60 of 116 (51.7%) vernakalant

2011 EvidenceUpdates Controlled trial quality: predicted high

17. Amiodarone Pulmonary Toxicity

Amiodarone Pulmonary Toxicity Amiodarone Pulmonary Toxicity Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Amiodarone Pulmonary (...) Toxicity Amiodarone Pulmonary Toxicity Aka: Amiodarone Pulmonary Toxicity From Related Chapters II. Epidemiology Occurs in 1-2% of patients on per year III. Pathophysiology Acute or subacute pneumonitis related to pulmonary drug deposition IV. Symptoms and cough may occur V. Differential Diagnosis VI. Imaging Diffuse s In some cases may appear similar to lobar CT Extensive bilateral alveolar and s Ground-glass opacities VII. Diagnosis Clinical diagnosis only (no lab or imaging study is diagnostic) s

2018 FP Notebook

18. Evaluation of the Pharmacokinetic Profile, Pharmacodynamic Effects, Acceptability and Tolerability of an Oral Amiodarone Solution of 15 mg / mL in Children With Supra Ventricular Tachycardia

registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Evaluation of the Pharmacokinetic Profile, Pharmacodynamic Effects, Acceptability and Tolerability of an Oral Amiodarone Solution of 15 mg / mL in Children With Supra Ventricular Tachycardia (Enteramio) The safety and scientific validity of this study is the responsibility (...) Evaluation of the Pharmacokinetic Profile, Pharmacodynamic Effects, Acceptability and Tolerability of an Oral Amiodarone Solution of 15 mg / mL in Children With Supra Ventricular Tachycardia Evaluation of the Pharmacokinetic Profile, Pharmacodynamic Effects, Acceptability and Tolerability of an Oral Amiodarone Solution of 15 mg / mL in Children With Supra Ventricular Tachycardia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting

2017 Clinical Trials

19. Intravenous Amiodarone versus Digoxin in Atrial Fibrillation Rate Control; a Clinical Trial. Full Text available with Trip Pro

Intravenous Amiodarone versus Digoxin in Atrial Fibrillation Rate Control; a Clinical Trial. Treatment of rapid ventricular response arterial fibrillation (rapid AF) varies depending on the decision of the in-charge physician, condition of the patient, availability of the drug, and the treatment protocol of the hospital. The present study was designed aiming to compare IV digoxin and amiodarone in controlling the heart rate of patients presenting to emergency department with rapid AF (...) and relative contraindication for first line drug in this regard.In the present clinical trial, patients presented to the ED with rapid AF and relative contraindication for calcium channel blockers and beta-blockers were treated with either IV amiodarone or IV digoxin and compared regarding success rate and complication using SPSS version 22. P < 0.05 was considered as statistically significant.84 patients were randomly allocated to either amiodarone or digoxin treatment groups of 42 (53.6% male). The mean

2017 Emergency (Tehran, Iran) Controlled trial quality: uncertain

20. A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation (AF) (MK-6621-055)

of vernakalant at a dose of 2 mg/kg (up to a maximum of 226 mg) will be administered. Other Name: Brinavess Active Comparator: Amiodarone Drug: Amiodarone Administered IV as per product label Other Names: Pacerone Cordarone Outcome Measures Go to Primary Outcome Measures : Number of participants discharged from the emergency room (ER) to home, home-equivalent, or long-term care facility (LTCF) within 12 hours from randomization [ Time Frame: Up to 12 hours from randomization ] Secondary Outcome Measures (...) A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation (AF) (MK-6621-055) A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation (AF) (MK-6621-055) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning

2012 Clinical Trials